Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$5.88 - $9.59 $64,521 - $105,231
10,973 New
10,973 $95,000
Q3 2019

Nov 14, 2019

SELL
$5.12 - $7.21 $3,927 - $5,530
-767 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$6.05 - $13.66 $4,640 - $10,477
767 New
767 $5,000
Q1 2019

May 15, 2019

SELL
$8.16 - $13.42 $7,384 - $12,145
-905 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$6.54 - $11.74 $621 - $1,115
95 Added 11.73%
905 $7,000
Q3 2018

Nov 14, 2018

BUY
$10.88 - $14.52 $8,812 - $11,761
810 New
810 $9,000
Q2 2018

Aug 14, 2018

SELL
$10.66 - $14.38 $9,657 - $13,028
-906 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$9.0 - $15.16 $3,744 - $6,306
416 Added 84.9%
906 $12,000
Q4 2017

Feb 14, 2018

SELL
$7.67 - $9.31 $50,698 - $61,539
-6,610 Reduced 93.1%
490 $5,000
Q3 2017

Nov 14, 2017

BUY
$5.95 - $8.26 $42,245 - $58,646
7,100
7,100 $57,000

Others Institutions Holding CBAY

About CymaBay Therapeutics, Inc.


  • Ticker CBAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,677,904
  • Description
  • CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...
More about CBAY
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.